Factors associated with pre-treatment hyperferritinemia in patients with chronic hepatitis C virus infection.

Humans Male Female Middle Aged Hepatitis C, Chronic / blood Hyperferritinemia / blood Ferritins / blood Adult Aged Hepacivirus Liver Cirrhosis / blood Alanine Transaminase / blood Risk Factors
Hepatitis B virus Hepatitis C virus Hyperferritinemia Metabolic dysfunction-associated steatotic liver disease

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 08 2024
Historique:
received: 19 05 2024
accepted: 14 08 2024
medline: 20 8 2024
pubmed: 20 8 2024
entrez: 19 8 2024
Statut: epublish

Résumé

Pre-treatment host and viral factors may affect serum ferritin levels in patients with hepatitis C virus (HCV) infection. We delineated pre-treatment factors associated with hyperferritinemia in these patients. 1682 eligible patients underwent pre-treatment assessment for serum ferritin and various host/viral factors. Univariate and multivariate logistic regression analyses were conducted to evaluate factors associated with hyperferritinemia. Multivariate logistic regression analyses revealed that age > 50 years (adjusted odds ratio [OR]: 1.38 (95% confidence interval [CI] 1.09-1.74), p = 0.008), fibrosis stage ≥ F3 (adjusted OR: 1.36 (95% CI 1.04-1.77), p = 0.02), fibrosis index based on four parameters (FIB-4) > 3.25 (adjusted OR: 1.46 (95% CI 1.11-1.92), p = 0.01), presence of metabolic dysfunction-associated steatotic liver disease (MASLD) (adjusted OR: 1.43 (95% CI 1.21-1.76), p = 0.001), and alanine transaminase (ALT) > 2 folds upper limit of normal (ULN) (adjusted OR: 2.87 (95% CI 2.20-3.75), p < 0.001) were associated hyperferritinemia. The log

Identifiants

DOI: 10.1038/s41598-024-70233-9 PMID: 39160295
pubmed: 39160295
doi: 10.1038/s41598-024-70233-9
pii: 10.1038/s41598-024-70233-9
doi:

Substances chimiques

Ferritins 9007-73-2
Alanine Transaminase EC 2.6.1.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19219

Subventions

Organisme : National Taiwan University Hospital
ID : 112-IF0004

Informations de copyright

© 2024. The Author(s).

Références

Cui, F. et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol. Hepatol. 8, 332–342 (2023).
doi: 10.1016/S2468-1253(22)00386-7 pubmed: 36764320
Sandnes, M., Ulvik, R. J., Vorland, M. & Reikvam, H. Hyperferritinemia—A clinical overview. J. Clin. Med. https://doi.org/10.3390/jcm10092008 (2021).
doi: 10.3390/jcm10092008 pubmed: 34067164 pmcid: 8125175
Koperdanova, M. & Cullis, J. O. Interpreting raised serum ferritin levels. BMJ. 351, h3692. https://doi.org/10.1136/bmj.h3692 (2015).
Wang, W., Knovich, M. A., Coffman, L. G., Torti, F. M. & Torti, S. V. Serum ferritin: Past, present and future. Biochim. Biophys. Acta 760–769, 2010. https://doi.org/10.1016/j.bbagen.2010.03.011 (1800).
doi: 10.1016/j.bbagen.2010.03.011
Adams, P. C. et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 352, 1769–1778. https://doi.org/10.1056/NEJMoa041534 (2005).
doi: 10.1056/NEJMoa041534 pubmed: 15858186
Gensluckner, S. et al. Prevalence and characteristics of metabolic hyperferritinemia in a population-based Central-European Cohort. Biomedicines. https://doi.org/10.3390/biomedicines12010207 (2024).
doi: 10.3390/biomedicines12010207 pubmed: 38255312 pmcid: 10813305
Ogilvie, C., Fitzsimons, K. & Fitzsimons, E. J. Serum ferritin values in primary care: are high values overlooked?. J. Clin. Pathol. 63, 1124–1126. https://doi.org/10.1136/jcp.2010.083188 (2010).
doi: 10.1136/jcp.2010.083188 pubmed: 20947869
Moreira, A. C., Mesquita, G. & Gomes, M. S. Ferritin: An inflammatory player keeping iron at the core of pathogen-host interactions. Microorganisms 8, 589 (2020).
doi: 10.3390/microorganisms8040589 pubmed: 32325688 pmcid: 7232436
Di Bisceglie, A. M., Axiotis, C. A., Hoofnagle, J. H. & Bacon, B. R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 102, 2108–2113. https://doi.org/10.1016/0016-5085(92)90339-z (1992).
doi: 10.1016/0016-5085(92)90339-z pubmed: 1587431
Georgopoulou, U., Dimitriadis, A., Foka, P., Karamichali, E. & Mamalaki, A. Hepcidin and the iron enigma in HCV infection. Virulence 5, 465–476 (2014).
doi: 10.4161/viru.28508 pubmed: 24626108 pmcid: 4063809
Chapoutot, C. et al. Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis. Gut 46, 711–714. https://doi.org/10.1136/gut.46.5.711 (2000).
doi: 10.1136/gut.46.5.711 pubmed: 10764717 pmcid: 1727940
Lambrecht, R. W. et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 140, 1490-1500.e1493. https://doi.org/10.1053/j.gastro.2011.01.053 (2011).
doi: 10.1053/j.gastro.2011.01.053 pubmed: 21335007
Ikura, Y., Morimoto, H., Johmura, H., Fukui, M. & Sakurai, M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am. J. Gastroenterol. 91, 1367–1373 (1996).
pubmed: 8677997
Ackerman, Z., Pappo, O. & Ben-Dov, I. Z. The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection. J. Med. Virol. 83, 1262–1268. https://doi.org/10.1002/jmv.22093 (2011).
doi: 10.1002/jmv.22093 pubmed: 21567428
Bonkovsky, H. L., Banner, B. F. & Rothman, A. L. Iron and chronic viral hepatitis. Hepatology 25, 759–768. https://doi.org/10.1002/hep.510250345 (1997).
doi: 10.1002/hep.510250345 pubmed: 9049232
Prati, D. et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 137, 1–10. https://doi.org/10.7326/0003-4819-137-1-200207020-00006 (2002).
doi: 10.7326/0003-4819-137-1-200207020-00006 pubmed: 12093239
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 (2009).
doi: 10.7326/0003-4819-150-9-200905050-00006 pubmed: 19414839 pmcid: 2763564
Liu, C. H. et al. Comparison of Abbott RealTime HCV genotype II with Versant line probe assay 20 for hepatitis C virus genotyping. J. Clin. Microbiol. 53, 1754–1757. https://doi.org/10.1128/jcm.03548-14 (2015).
doi: 10.1128/jcm.03548-14 pubmed: 25740780 pmcid: 4400777
Castera, L., Forns, X. & Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol. 48, 835–847. https://doi.org/10.1016/j.jhep.2008.02.008 (2008).
doi: 10.1016/j.jhep.2008.02.008 pubmed: 18334275
Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556. https://doi.org/10.1016/j.jhep.2023.06.003 (2023).
doi: 10.1016/j.jhep.2023.06.003 pubmed: 37364790
Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022–1030. https://doi.org/10.1016/j.jhep.2016.12.022 (2017).
doi: 10.1016/j.jhep.2016.12.022 pubmed: 28039099
Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325. https://doi.org/10.1002/hep.21178 (2006).
doi: 10.1002/hep.21178 pubmed: 16729309
McKinnon, E. J., Rossi, E., Beilby, J. P., Trinder, D. & Olynyk, J. K. Factors that affect serum levels of ferritin in Australian adults and implications for follow-up. Clin. Gastroenterol. Hepatol. 12, 101-108.e104 (2014).
doi: 10.1016/j.cgh.2013.07.019 pubmed: 23906872
Choi, K. M. et al. Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism 54, 1510–1514. https://doi.org/10.1016/j.metabol.2005.05.018 (2005).
doi: 10.1016/j.metabol.2005.05.018 pubmed: 16253641
Branten, A. J., Swinkels, D. W., Klasen, I. S. & Wetzels, J. F. Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. Nephrol. Dialysis Transpl. 19, 2754–2760 (2004).
doi: 10.1093/ndt/gfh454
Moucari, R. et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134, 416–423. https://doi.org/10.1053/j.gastro.2007.11.010 (2008).
doi: 10.1053/j.gastro.2007.11.010 pubmed: 18164296
Maeno, T. et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J. Gastroenterol. Hepatol. 18, 1358–1363. https://doi.org/10.1046/j.1440-1746.2003.03179.x (2003).
doi: 10.1046/j.1440-1746.2003.03179.x pubmed: 14675263
Negro, F. HCV infection and metabolic syndrome: Which is the chicken and which is the egg?. Gastroenterology 142, 1288–1292. https://doi.org/10.1053/j.gastro.2011.12.063 (2012).
doi: 10.1053/j.gastro.2011.12.063 pubmed: 22537435
Adinolfi, L. E. et al. NAFLD and NASH in HCV infection: Prevalence and significance in hepatic and extrahepatic manifestations. Int. J. Mol. Sci. 17, 803. https://doi.org/10.3390/ijms17060803 (2016).
doi: 10.3390/ijms17060803 pubmed: 27231906 pmcid: 4926337
Kowdley, K. V. et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55, 77–85. https://doi.org/10.1002/hep.24706 (2012).
doi: 10.1002/hep.24706 pubmed: 21953442
Manousou, P. et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int. 31, 730–739. https://doi.org/10.1111/j.1478-3231.2011.02488.x (2011).
doi: 10.1111/j.1478-3231.2011.02488.x pubmed: 21457446
Moris, W., Verhaegh, P., Jonkers, D., Deursen, C. V. & Koek, G. Hyperferritinemia in nonalcoholic fatty liver disease: Iron accumulation or inflammation?. Semin. Liver Dis. 39, 476–482. https://doi.org/10.1055/s-0039-1693114 (2019).
doi: 10.1055/s-0039-1693114 pubmed: 31330553
Pinzani, M., Rombouts, K. & Colagrande, S. Fibrosis in chronic liver diseases: Diagnosis and management. J. Hepatol. 42(Suppl), S22-36. https://doi.org/10.1016/j.jhep.2004.12.008 (2005).
doi: 10.1016/j.jhep.2004.12.008 pubmed: 15777570
Ginès, P. et al. Screening for liver fibrosis in the general population: A call for action. Lancet Gastroenterol. Hepatol. 1, 256–260. https://doi.org/10.1016/s2468-1253(16)30081-4 (2016).
doi: 10.1016/s2468-1253(16)30081-4 pubmed: 28404098
Younes, R. et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?. Gut 71, 382–390. https://doi.org/10.1136/gutjnl-2020-322564 (2022).
doi: 10.1136/gutjnl-2020-322564 pubmed: 33541866
Armandi, A. et al. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut 73, 825–834. https://doi.org/10.1136/gutjnl-2023-330815 (2024).
doi: 10.1136/gutjnl-2023-330815 pubmed: 38199805
Gervais, A. et al. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. J. Hepatol. 35, 399–405. https://doi.org/10.1016/s0168-8278(01)00138-6 (2001).
doi: 10.1016/s0168-8278(01)00138-6 pubmed: 11592602
Luo, J. et al. Serum ferritin diagnosis and prediction of hepatitis B virus-related acute-on-chronic liver failure. J. Med. Virol. 95, e28183. https://doi.org/10.1002/jmv.28183 (2023).
doi: 10.1002/jmv.28183 pubmed: 36175010
Mavilia, M. G. & Wu, G. Y. HBV-HCV coinfection: Viral interactions, management, and viral reactivation. J. Clin. Transl. Hepatol. 6, 296–305. https://doi.org/10.14218/jcth.2018.00016 (2018).
doi: 10.14218/jcth.2018.00016 pubmed: 30271742 pmcid: 6160312
Dai, C. Y. et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 16, 636–640. https://doi.org/10.1046/j.1440-1746.2001.02494.x (2001).
doi: 10.1046/j.1440-1746.2001.02494.x pubmed: 11422616

Auteurs

Yu-Ping Chang (YP)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.

Chiuan-Bo Huang (CB)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.

Jia-Horng Kao (JH)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.

Tung-Hung Su (TH)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.

Shang-Chin Huang (SC)

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.

Tai-Chung Tseng (TC)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.

Pei-Jer Chen (PJ)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.

Chun-Jen Liu (CJ)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan. cjliu@ntu.edu.tw.
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. cjliu@ntu.edu.tw.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. cjliu@ntu.edu.tw.

Chen-Hua Liu (CH)

Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 10002, Taiwan. jacque_liu@mail2000.com.tw.
Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. jacque_liu@mail2000.com.tw.
Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan. jacque_liu@mail2000.com.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Factors associated with pre-treatment...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Factors associated with pre-treatment...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Hépatite chronique › Hépatite C chronique › Factors associated with pre-treatment...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles du métabolisme du fer › Hyperferritinémie › Factors associated with pre-treatment...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Métalloprotéines › Protéines de liaison au fer › Ferritines › Factors associated with pre-treatment...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Factors associated with pre-treatment...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Factors associated with pre-treatment...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Hepacivirus › Factors associated with pre-treatment...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Cirrhose du foie › Factors associated with pre-treatment...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Nitrogenous group transferases › Transaminases › Alanine transaminase › Factors associated with pre-treatment...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Factors associated with pre-treatment...